Tag: ROTH Capital Partners

April 20, 2018

Inpixon Prices $9 Million Public Offering in an Effort to Satisfy Nasdaq’s Stockholders’ Equity Requirement

Inpixon (NASDAQ:INPX), a leading data analytics company announced the pricing of a public offering with anticipated gross proceeds of $9...
March 5, 2018

RESAAS to Present at 30th Annual ROTH Capital Conference in Dana Point, CA

RESAAS Services Inc. (CSE:RSS, OTCQX:RSASF), a cloud-based social business platform for the real estate services industry, will present at the...
February 16, 2018

Moleculin Announces Pricing of $9 Million Registered Direct Offering

Moleculin Biotech (NASDAQ: MBRX) a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are...
February 8, 2018

Gemphire Announces Pricing of $22 Million Public Offering of Common Stock

Gemphire Therapeutics (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, Non Alcoholic...
February 1, 2018

Q Biomed Inc. Closes $5.48 Million Public Offering

Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce the closing of its...
January 25, 2018

Eyenovia Announces Pricing of Initial Public Offering

Eyenovia (NASDAQ:EYEN) a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics...
January 25, 2018

Albireo Prices $65.0 Million Public Offering of Common Stock

Albireo Pharma (Nasdaq:ALBO) a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of...